Boston Scientific price target lowered to $84 from $87 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Boston Scientific (BSX) to $84 from $87 but keeps a Buy rating on the shares after its Q1 results. An in-line quarter on both the top- and bottom-lines and a rebase of the forward outlook created a clearing event for the stock the analyst tells investors in a research note. Of most significance to the update, the Q2-Q4 revenue cadence now contemplates a deceleration in growth of about 6.5% vs. the 9.4% reported in Q1 to achieve the mid-point of FY targets, whereas the original guidance included an acceleration, the firm added.